Amerikanische Gesellschaft für Hirudotherapie

Small Localized Subcutaneous Lipoma

Highly investigational use for small subcutaneous lipoma (<3 cm) with cosmetic concern; surgical excision remains standard; very limited data.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for small localized subcutaneous lipoma. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). Anecdotal reports describe local softening of lipomas after leech sessions, but lipomas are benign fatty tumors that do not require any treatment unless symptomatic or growing. Evidence-based management of a symptomatic lipoma is surgical excision under local anesthesia, which is curative; for asymptomatic small lipomas, observation alone is appropriate.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Bleeding into the lipoma (hematoma)
  • Misdiagnosis if the lump is actually a liposarcoma or other malignancy and is delayed from proper biopsy
Wer dies nicht in Betracht ziehen sollte
  • Patients with a rapidly enlarging, hard, painful, or fixed lump (needs imaging and biopsy first — could be sarcoma)
  • Patients with multiple deep lipomas, family history of lipomatosis, or Dercum disease (different workup needed)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • Has the lump been confirmed as a lipoma by ultrasound or biopsy?
  • Why am I considering treatment if it is small, soft, and asymptomatic?
  • Would a 10-15 minute outpatient excision be curative and definitive?
  • What is the published evidence for leeches reducing lipoma size?
  • What is the risk that this delays a more serious diagnosis if the lump is not actually a lipoma?
  • How would success be measured — ultrasound size, patient-reported, both?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Rapid growth, hardening, fixation to underlying tissue, or new pain in the lump
  • Skin changes over the lump such as ulceration or color change

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for lipomas — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace surgical excision, which is curative for symptomatic or growing lipomas.
  • It does not differentiate between a benign lipoma and a liposarcoma — that requires imaging and biopsy.
  • It does not have RCT evidence supporting lipoma size reduction.
  • It does not address most lipomas, which need no treatment at all.

Clinical Profile

Category
dermatological
ICD-10
D17.0, D17.1, D17.20, D17.21, D17.22, D17.9
Safety tier
low

Evidence Summary

Subcutaneous lipomas are benign, and definitive management is surgical excision (especially for lesions >3 cm, painful, or cosmetically problematic) or observation. Direct evidence for leech therapy is minimal: a single mixed-indication clinical series from Azerbaijan included a small lipoma subgroup (n=8) and reported subjective symptom improvement, while explicitly noting that hirudotherapy did not reverse structural changes or tissue loss. This is grade D, exploratory, and uncontrolled; any apparent change in a palpable lipoma may reflect measurement variability rather than true adipocyte depletion. Patients should be informed that surgical excision remains the standard with a predictable outcome, and histologic confirmation may be appropriate before any conservative trial.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Kumar V et al. (2020), n=10

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Suspected liposarcoma (rapidly growing, deep, fixed) — surgical biopsy
  • Lipoma >3 cm or in cosmetically critical area (surgery preferred)
  • Madelung disease or multiple symmetric lipomatosis

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Small Localized Subcutaneous Lipoma — Hirudotherapy Evidence | ASH